We are live on ! Find out more
PCM

Peregrine Capital Management Portfolio holdings

AUM $3.08B
1-Year Est. Return 29.51%
This Fund
S&P 500
This Quarter Est. Return
+6.76%
1 Year Est. Return
+29.51%
3 Year Est. Return
+95.04%
5 Year Est. Return
+107.83%
10 Year Est. Return
+715.34%
AUM
$3.38B
AUM Growth
+$66.8M
Cap. Flow
-$73.5M
Cap. Flow %
-2.18%
Top 10 Hldgs %
25.62%
Holding
354
New
31
Increased
99
Reduced
136
Closed
24

Top Buys

Rank Stock Value
1
PCOR icon
Procore
PCOR
+$38M
2
FLUT icon
Flutter Entertainment
FLUT
+$31.6M
3
SYNA icon
Synaptics
SYNA
+$10.5M
4
AAON icon
Aaon
AAON
+$8.88M
5
ROAD icon
Construction Partners
ROAD
+$8.04M

Top Sells

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$26.7M
2
ARES icon
Ares Management
ARES
+$22.4M
3
MA icon
Mastercard
MA
+$10.9M
4
V icon
Visa
V
+$10.7M
5
AMZN icon
Amazon
AMZN
+$9.91M

Sector Composition

Rank Sector Weight
1 Technology 28.46%
2 Financials 15.72%
3 Healthcare 15.15%
4 Consumer Discretionary 13.81%
5 Industrials 9.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SJM icon
326
J.M. Smucker
SJM
$12.6B
$9.91K ﹤0.01%
90
– –
NOV icon
327
NOV
NOV
$7.41B
$9.64K ﹤0.01%
660
– –
BWA icon
328
BorgWarner
BWA
$14.1B
$8.11K ﹤0.01%
255
– –
PII icon
329
Polaris
PII
$3.87B
$7.2K ﹤0.01%
125
– –
HUN icon
330
Huntsman Corp
HUN
$1.79B
$6.49K ﹤0.01%
360
– –
AES icon
331
AES
AES
$10.5B
– –
-1,280
Closed -$25.7K
APA icon
332
APA Corp
APA
$14.1B
– –
-375
Closed -$9.17K
APLS
333
DELISTED
Apellis Pharmaceuticals
APLS
– –
-114,533
Closed -$3.3M
APLT
334
DELISTED
Applied Therapeutics
APLT
– –
-664,740
Closed -$5.65M
CVSA
335
Covista Inc
CVSA
$4.31B
– –
-58,459
Closed -$4.41M
CHRS icon
336
Coherus Oncology
CHRS
$184M
– –
-734,877
Closed -$764K
CNXC icon
337
Concentrix
CNXC
$1.53B
– –
-180
Closed -$9.22K
COHR icon
338
Coherent
COHR
$68.9B
– –
-400
Closed -$35.6K
CUBI icon
339
Customers Bancorp
CUBI
$2.78B
– –
-121,095
Closed -$5.62M
EAT icon
340
Brinker International
EAT
$10B
– –
-75,604
Closed -$5.79M
EW icon
341
Edwards Lifesciences
EW
$53.3B
– –
-405,261
Closed -$26.7M
IIPR icon
342
Innovative Industrial Properties
IIPR
$1.68B
– –
-53,629
Closed -$7.22M
IONS icon
343
Ionis Pharmaceuticals
IONS
$9.39B
– –
-131,630
Closed -$5.27M
OPLN
344
Openlane
OPLN
$4.27B
– –
-351,557
Closed -$5.93M
LULU icon
345
lululemon athletica
LULU
$13.8B
– –
-21
Closed -$5.7K
OEC icon
346
Orion
OEC
$369M
– –
-399,710
Closed -$7.12M
PLAY icon
347
Dave & Buster's
PLAY
$352M
– –
-181,981
Closed -$6.2M
SITC icon
348
SITE Centers
SITC
$156M
– –
-473,684
Closed -$5.59M
SNDR icon
349
Schneider National
SNDR
$6.25B
– –
-251,456
Closed -$7.18M
SNDX icon
350
Syndax Pharmaceuticals
SNDX
$1.83B
– –
-199,086
Closed -$3.83M
11 12 13
14
15

Similar funds

CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
MRCP
Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
SAG
Susquehanna Advisors Group Bala Cynwyd, Pennsylvania $3.05B AUM 41.49% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Peregrine Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Peregrine Capital Management held 354 positions worth $3.38B, up 2% from $3.31B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Peregrine Capital Management's Q4 2024 filing shows 31 new, 99 increased, 136 reduced and 24 closed positions. Its largest new stake was Procore: 535,699 shares worth $40.1M. The largest sale was Edwards Lifesciences, an estimated $26.7M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.

  • Peregrine Capital Management's largest Q4 2024 buy was Procore: 535,699 shares worth $40.1M.
  • Peregrine Capital Management added most to Synaptics in Q4 2024, an estimated $10.5M increase.
  • Peregrine Capital Management's biggest Q4 2024 reduction was Ares Management, cutting an estimated $22.4M.
  • Peregrine Capital Management fully exited Edwards Lifesciences in Q4 2024, selling an estimated $26.7M.
  • Peregrine Capital Management's ten largest holdings make up 26% of its $3.38B portfolio in Q4 2024.
  • Peregrine Capital Management opened 31 new positions and closed 24 in Q4 2024.
  • Peregrine Capital Management's portfolio value rose 2% quarter-over-quarter to $3.38B.

Based on Peregrine Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.